Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Cancer Survival Analysis01:21

Cancer Survival Analysis

857
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
857
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.

Scientific reports·2026
Same author

Correction: Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.

Intensive care medicine·2025
Same author

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.

Intensive care medicine·2025
Same author

Radiation-Induced Lymphopenia: From Mathematical Modeling Toward Mechanistic Learning.

International journal of radiation oncology, biology, physics·2025
Same author

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.

The journal of liquid biopsy·2025

Related Experiment Video

Updated: Apr 26, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K

Metronomics chemotherapy: time for computational decision support.

Dominique Barbolosi1, Joseph Ciccolini, Christophe Meille

  • 1SMARTc Pharmacokinetics Unit, School of Pharmacy, Inserm S_911 CRO2 Aix-Marseille University, 27 Bd Jean Moulin, 13385, Marseille 05, France.

Cancer Chemotherapy and Pharmacology
|August 2, 2014
PubMed
Summary
This summary is machine-generated.

Metronomic chemotherapy, using low-dose vinorelbine, shows promise for cancer treatment. Mathematical modeling can optimize these schedules for better efficacy and reduced toxicity, moving beyond empirical practices.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
08:25

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

17.7K

Related Experiment Videos

Last Updated: Apr 26, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
08:25

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

17.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Computational Biology

Background:

  • Metronomic chemotherapy, characterized by frequent low doses of cytotoxic agents, is gaining traction for its potential to reduce toxicity and exhibit novel anti-cancer mechanisms.
  • Vinorelbine, a vinca-alkaloid, is a key drug in treating metastatic breast cancer, non-small cell lung cancer, and pediatric solid tumors, with a new oral formulation enabling metronomic scheduling.
  • Current clinical trials on metronomic vinorelbine have yielded inconsistent results due to empirical determination of dosing schedules, highlighting the need for a more scientific approach.

Purpose of the Study:

  • To review recent clinical trials investigating metronomic vinorelbine and its efficacy/toxicity balance.
  • To propose computational strategies, specifically mathematical modeling, for optimizing metronomic vinorelbine schedules.
  • To advocate for a science-grounded approach to metronomic chemotherapy, moving beyond empirical bedside practices.

Main Methods:

  • Review of existing clinical trials on metronomic vinorelbine in adult and pediatric oncology.
  • Exploration of mathematical modeling and pharmacokinetics/pharmacodynamics (PK/PD) constraint models for in silico optimization of drug schedules.
  • Analysis of potential PK/PD modeling applications for lung cancer treatment with metronomic vinorelbine.

Main Results:

  • Clinical trials on metronomic vinorelbine have shown varied outcomes, suggesting that empirical dosing is insufficient for optimal results.
  • Mathematical modeling offers a powerful tool to navigate the complex parameter space of metronomic schedules and identify optimal protocols.
  • PK/PD constraint models can provide valuable insights for developing evidence-based metronomic vinorelbine regimens, particularly for lung cancer.

Conclusions:

  • Metronomic vinorelbine holds therapeutic potential, but its effectiveness is highly dependent on optimized dosing schedules.
  • Computational decision support systems utilizing mathematical modeling are crucial for establishing metronomic chemotherapy as a scientifically validated strategy.
  • Further research integrating PK/PD modeling is recommended to refine metronomic vinorelbine scheduling for improved patient outcomes in lung cancer and other malignancies.